GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium
28. Juni 2023 07:00 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new...
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
05. Dezember 2022 08:00 ET
|
Sema4
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings...
Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET
28. April 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5,...
Raptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate Update
25. Februar 2016 16:05 ET
|
Raptor Pharmaceutical Inc
2015 Global Net Revenue for PROCYSBI® of $94.2 Million Reported 2016 Global Net Revenue Guidance of $115 to $125 Million 2016 Anticipated PROCYSBI Growth of 25%-30% Year-Over Year Company to Host...
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25, 2016, at 4:30 p.m. ET
18. Februar 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release fourth quarter and full year 2015 financial results on...
Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity
25. Januar 2016 07:05 ET
|
Raptor Pharmaceutical Inc
Five Patents for PROCYSBI Now Listed in FDA Orange Book Orphan Drug Exclusivity Extended in Nephropathic Cystinosis Patients 2-6 Years Old NOVATO, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Raptor...
Raptor Pharmaceutical to Hold Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, November 5, 2015, at 4:30 p.m. ET
29. Oktober 2015 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2015 financial results on Thursday, November 5,...
Raptor Pharmaceutical Completes Acquisition of Quinsair(TM)
05. Oktober 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution)...
Raptor Pharmaceutical to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable
23. September 2015 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:
Julie Anne Smith,...